Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors

Udai Banerji, Simon Pacey, Karen Finkelstein, Simon Rodney, Ana Filipa Palma DosReis, Giovanni Codaccipisanelli, Mark Sloan, Florence I Raynaud, Ruth Ruddle, Karen Swales, Matthew Tall, Shay Shemesh, Diane Marsolini, Megan Sardone, Justin Hay, Robin Bliss, Enrique Poradosu, Paul Workman

Mol Cancer Ther (2023) 22 (12_Supplement): B044.

https://doi.org/10.1158/1535-7163.TARG-23-B044

Published: 01 December 2023

View article titled, Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors

Journal Articles

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Elizabeth A. Coker, Adam Stewart, Bugra Ozer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O'Brien, Florence Raynaud, Johann de Bono, Bissan Al-Lazikani, Udai Banerji

Mol Cancer Ther (2022) 21 (6): 1020–1029.

https://doi.org/10.1158/1535-7163.MCT-21-0442

Published: 01 June 2022

View article titled, Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Includes: Supplementary data

Journal Articles

Abstract P036: Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant NSCLC

Thubeena Manickavasagar, Chara Stavraka, Kaiser Anam, Silvia Coma, Sanjib Chowdhury, Jonathan A. Pachter, Tom Parker, Mona Parmar, Laura Finneran, Emma Hall, James Spicer, Anna Minchom, Udai Banerji

Mol Cancer Ther (2021) 20 (12_Supplement): P036.

https://doi.org/10.1158/1535-7163.TARG-21-P036

Published: 01 December 2021

View article titled, Abstract P036: Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant NSCLC

Journal Articles

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer

Charlotte K. Milton, Annette J. Self, Paul A. Clarke, Udai Banerji, Federica Piccioni, David E. Root, Steven R. Whittaker

Mol Cancer Ther (2020) 19 (7): 1423–1435.

https://doi.org/10.1158/1535-7163.MCT-19-1131

Published: 02 July 2020

View article titled, A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer

Includes: Supplementary data

Journal Articles

Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors

Albert A Antolin, Malaka Ameratunga, Udai Banerji, Paul Clarke, Paul Workman, Bissan Al-Lazikani

Mol Cancer Ther (2019) 18 (12_Supplement): LB-C01.

https://doi.org/10.1158/1535-7163.TARG-19-LB-C01

Published: 01 December 2019

View article titled, Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors

Journal Articles

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl, Alexandros Georgiou, Anna R. Minchom, Suzanne Carreira, David Cunningham, Mary ER. O'Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al-Lazikani, Udai Banerji

Mol Cancer Ther (2019) 18 (8): 1396–1404.

https://doi.org/10.1158/1535-7163.MCT-18-0727

Published: 01 August 2019

View article titled, Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

Includes: Supplementary data

Journal Articles

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, Yutaka Fujiwara, Shigenobu Suzuki, Noriko Yanagitani, Atsushi Horiike, Satoru Kitazono, Fumiyoshi Ohyanagi, Toshihiko Doi, Yasutoshi Kuboki, Akihito Kawazoe, Kohei Shitara, Izumi Ohno, Udai Banerji, Raghav Sundar, Shuichi Ohkubo, Elizabeth M. Calleja, Makoto Nishio

Mol Cancer Ther (2019) 18 (3): 531–540.

https://doi.org/10.1158/1535-7163.MCT-18-0831

Published: 01 March 2019

View article titled, First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Journal Articles

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Joo Ern Ang, Akos Pal, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de haven Brandon, Victoria L. Revell, Debra J. Skene, Miro Venturi, Ruediger Rueger, Valerie Meresse, Suzanne A. Eccles, Johann S. de Bono, Stanley B. Kaye, Paul Workman, Udai Banerji, Florence I. Raynaud

Mol Cancer Ther (2017) 16 (10): 2315–2323.

https://doi.org/10.1158/1535-7163.MCT-16-0881

Published: 02 October 2017

View article titled, Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Includes: Supplementary data

Journal Articles

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

Mol Cancer Ther (2015) 14 (12_Supplement_2): B109.

https://doi.org/10.1158/1535-7163.TARG-15-B109

Published: 01 December 2015

View article titled, Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

Journal Articles

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

Mol Cancer Ther (2015) 14 (12_Supplement_2): PR14.

https://doi.org/10.1158/1535-7163.TARG-15-PR14

Published: 01 December 2015

View article titled, Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

Journal Articles

Abstract C173: A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.

Marta Capelan, Prasana Kumar, Anthony W. Tolcher, Andrea Zivi, Madhuri Desai, Kyriakos P. Papadopoulos, Giorgio Senaldi, Amita Patnaik, Udai Banerji, Drew D. Rasco

Mol Cancer Ther (2013) 12 (11_Supplement): C173.

https://doi.org/10.1158/1535-7163.TARG-13-C173

Published: 01 November 2013

View article titled, Abstract C173: A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.

Journal Articles

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Craig P. Carden, Adam Stewart, Parames Thavasu, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye, Udai Banerji

Mol Cancer Ther (2012) 11 (7): 1609–1617.

https://doi.org/10.1158/1535-7163.MCT-11-0996

Published: 05 July 2012

View article titled, The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Includes: Supplementary data

Journal Articles

Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

Aung Naing, Carol Aghajanian, Eric Raymond, Razelle Kurzrock, Montserrat Blanco, Elisabeth Oelmann, Lynda Grinsted, Wendy Burke, Stan Kaye, Udai Banerji

Mol Cancer Ther (2011) 10 (11_Supplement): A168.

https://doi.org/10.1158/1535-7163.TARG-11-A168

Published: 12 November 2011

View article titled, Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

Journal Articles

Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer.

Rebecca S. Kristeleit, Richard D. Baird, Balaji Venugopal, Duncan K. Wilkins, Fiona MacCormick, Roberta Granata, Donna Crawford, Julie Charlton, John Camm, Peter Hellemans, Nele Fourneau, Yusri Elsayed, Richard Cowan, Udai Banerji, Ruth Plummer, Jeff Evans, Johann de Bono

Mol Cancer Ther (2011) 10 (11_Supplement): A164.

https://doi.org/10.1158/1535-7163.TARG-11-A164

Published: 12 November 2011

View article titled, Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer.

Journal Articles

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Udai Banerji, Annette Affolter, Ian Judson, Richard Marais, Paul Workman

Mol Cancer Ther (2008) 7 (4): 737–739.

https://doi.org/10.1158/1535-7163.MCT-08-0145

Published: 15 April 2008

View article titled, BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

NARROW

Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Abstract P036: Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant NSCLC

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer

Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

Abstract C173: A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer.

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only